• Home
  • About
  • Technology
  • Pipeline
  • Investors
  • Contact
  • About
  • Technology
    • KIO-101
    • KIO-201
    • KIO-301
  • Pipeline
  • Investors & News
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
    • Email Signup
Contact MENU

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • Email Signup
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
Sep 26, 2022 6:45am EDT

Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split

Sep 15, 2022 12:23pm EDT

Kiora Pharmaceuticals To Participate in the Ladenburg Thalmann 2022 Healthcare Conference

Sep 13, 2022 6:45am EDT

Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance

Aug 16, 2022 1:40pm EDT

"I'm going blind. This is what I want to you see." - NYT short film on RP

Aug 12, 2022 6:45am EDT

Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results

Aug 09, 2022 11:00am EDT

Kiora Pharmaceuticals To Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference; Online Presentation Will Be Available August 17, 2022 at 7:00 am EST

Jul 28, 2022 6:45am EDT

Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics

Jul 26, 2022 4:38pm EDT

Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Jul 22, 2022 8:30am EDT

Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering

Jul 05, 2022 6:45am EDT

Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …17
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
332 Encinitas Boulevard
Suite 102
Encinitas, CA 92024
info@kiorapharma.com
Twitter LinkedIn
©2023 Kiora Pharmaceuticals, Inc.
AboutManagement TeamBoard of DirectorsScientific Advisory BoardTechnologyKIO-101KIO-201KIO-301Pipeline
Investors Overview News & Events Company Info Financial Info Stock Data SEC Filings Governance Email Signup
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie Duration Description
cookielawinfo-checkbox-analytics 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional 11 months The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary 11 months This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy 11 months The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT